Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Leases (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Current Leases for 5 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 36.82% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 36.82% increase, with the full-year FY2025 number at $2.4 million, up 36.82% from a year prior.
  • Current Leases was $2.4 million for Q4 2025 at Janux Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.4 million in Q4 2025 to a low of $88000.0 in Q2 2022.
  • A 5-year average of $1.3 million and a median of $1.5 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 1500.0% in 2023, then increased 14.91% in 2025.
  • Janux Therapeutics' Current Leases stood at $194000.0 in 2021, then skyrocketed by 293.3% to $763000.0 in 2022, then surged by 98.82% to $1.5 million in 2023, then rose by 15.29% to $1.7 million in 2024, then surged by 36.82% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Current Leases are $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $1.9 million (Q2 2025).